Bayer Schering Pharma (Logo)
Bayer Heathcare (Logo)
  • Sitemap
  • RSS
  • Contact us
Home
  • Company
    • Our Biotech Leadership
    • Corporate Social Responsibility
  • Locations
    • Berkeley
    • Emeryville
    • Richmond
    • Seattle
  • Products
    • Bayer AG
    • About Betaseron®
    • About Kogenate®
    • About Leukine®
  • Research & Development
    • R&D Groups
    • Key Development Projects
  • Biomanufacturing
    • Berkeley
    • Emeryville
    • Seattle
  • Partnering
    • Opportunities
  • Careers
    • Current Openings
    • Employee Profiles
    • Benefits
    • Diversity
    • Internships
  • Newsroom
    • News
    • Media Contacts
    • RSS
  • Locations
  • Berkeley
  • Emeryville
  • Richmond
  • Seattle
    Country Links

    Bayer Links
    • Bayer Global
    • Bayer HealthCare Global
    • Investor Relations
    • General Conditions of Use
    • Privacy Statement
    • Imprint

    Copyright ©
    Bayer HealthCare

    Bayer HealthCare Pharmaceuticals in Seattle, Washington

    Bayer HealthCare Pharmaceuticals presently operates four facilities in three communities in the greater Seattle area: Bothell, Lynnwood and Seattle. Employees at these locations are dedicated to the manufacture of Leukine® (sargramostim), a growth factor that helps fight infection and disease in appropriate patients by enhancing immune cell function.

    The flagship facility of this supply center is a new manufacturing center in the early stages of licensure. Once complete and licensed by the US Food and Drug Administration, Bayer will consolidate all Leukine® supply operations to the new manufacturing center. This 95,000 square foot center is located on a 16-acre site in Lynnwood.

    Seattle Area Mailing Addresses:

    21511 23rd Drive S.E.
    Bothell, WA 98021
    (425) 908-3300

    2625 162nd Street SW
    Lynnwood, WA 98087
    (425) 245-1221

    1191 Second Ave, Suite 1200
    Seattle, WA 98101
    (206) 254-7700

    * LEUKINE® (sargramostim) is a recombinant granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) for use following induction chemotherapy in older adults with acute myelogenous leukemia (AML) to shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death. LEUKINE is also used in multiple stem cell transplantation settings click here to read the full indications.

    Important Information
    In controlled clinical trials across all indications, no significant differences were observed between LEUKINE® (sargramostim) and placebo-treated patients in the type or frequency of adverse events with the exception of an increase in skin-associated events in the LEUKINE group in the pivotal AML trial. There were occasional reports of fluid retention, dyspnea, supraventricular tachycardia, and laboratory abnormalities (increases in creatinine, bilirubin, and liver enzymes). Other adverse events have been reported. Please see full prescribing information which contains a more complete listing of indications, contraindications, warnings, precautions, adverse reactions, and dosage and administration guidelines


    Seattle building

    Learn more about:

    • Seattle’s biomanufacturing
    • Leukine® (sargramostim) and AML
    Font size
    -+ Font Sizer Control

    click to adjust

    Page tools
    • Printer friendly version
    • Bookmark this page
    • Email Us
    Search